Santorvastin 40 Adverse Reactions

Atorvastatin is generally well-tolerated. Adverse reactions have usually been mild and transient.
The most frequent adverse effects associated with Atorvastatin therapy in were: Infections and infestations: Nasopharyngitis.
Respiratory, Thoracic and Mediastinal Disorders: Pharyngolaryngeal pain, epistaxis.
Psychiatric Disorders: Insomnia, nightmare.
Nervous System Disorders: Headache.
Gastrointestinal Disorders: Nausea, diarrhea, abdominal pain, dyspepsia, constipation, flatulence.
Musculoskeletal and Connective Tissue Disorders: Myalgia, arthralgia, pain in extremity, musculoskeletal pain, muscle spasms, joint swelling.
Investigations: Liver function test abnormal, blood creatine phosphokinase increased.
General Disorders and Administration Site Conditions: Asthenia.
The following additional adverse effects have been reported in Atorvastatin: Vision blurred; hypoglycemia, hyperglycemia, anorexia; peripheral neuropathy, paresthesia; tinnitus; pancreatitis, vomiting, abdominal discomfort, eructation; hepatitis, cholestatic jaundice; alopecia, pruritus, rash, urticaria; myopathy, myositis, muscle cramps, muscle fatigue, neck pain; impotence; angioneurotic edema, malaise, pyrexia; angina; white blood cells urine positive.
Pediatric Patients (ages 10-17 years): Patients treated with Atorvastatin had an adverse experience profile generally similar to that of patients treated with placebo, the most common adverse experiences observed in both groups, regardless of causality assessment, were infections.
In post-marketing experience, the following additional undesirable effects have been reported: Thrombocytopenia; allergic reactions (including anaphylaxis); tendon rupture; weight gain; hypoesthesia, amnesia, dizziness, dysgeusia; pancreatitis; Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, erythema multiforme, bullous rashes; rhabdomyolysis, immune mediated necrotizing myopathy, myositis, back pain; chest pain, peripheral edema, fatigue.